1 Min Read
Jan 23 (Reuters) - CANTARGIA AB:
* CANTARGIA’S EUROPEAN PATENT FOR HAEMATOLOGICAL CANCERS REMAINS IN FORCE Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.